In regenerative medicine, experience matters. When a practitioner has spent more than two decades working across trauma, orthopaedics, aesthetics and regenerative medicine – while also training healthcare professionals internationally – their choice of technology carries weight.

That is why the experience of Claudia McGloin RGN is particularly relevant for practitioners considering Platelet-Rich Plasma (PRP) and autologous regenerative treatments.

As Clinical Director of The Regenerative Expert Nurse Clinic in Sligo, Ireland, Claudia has built a reputation as one of the country’s leading authorities on PRP and regenerative medicine. With more than 28 years of nursing experience and over 16 years dedicated to regenerative and aesthetic medicine, she combines extensive clinical expertise with a strong commitment to education, research and patient safety.

Today, Cellenis® PRP and Cellenis® DermaFiller form an important part of her treatment offering. The decision to adopt the systems was not driven by marketing claims or headline platelet counts. It was driven by the science behind the technology and the consistency of the product being produced.

A Career Dedicated to Regenerative Medicine

Claudia’s career spans advanced trauma and orthopaedic nursing, aesthetics, women’s health, hair restoration, intimate wellness and regenerative medicine.

She serves on the Editorial Boards of both the Journal of Aesthetic Nursing and Aesthetic Medicine, regularly publishes peer-reviewed articles and presents internationally on regenerative medicine and PRP.

She is also a Key Opinion Leader and international trainer for Cellenis, helping healthcare professionals better understand evidence-based PRP applications across multiple indications.

Her clinic specialises in a broad range of regenerative and restorative treatments, including skin rejuvenation, hair restoration, orthopaedic applications, women’s health and menopause support, intimate wellness and advanced regenerative medicine. This breadth of experience allows her to see first-hand how regenerative medicine can be applied across a wide range of patient needs.

Across all of these indications, one principle remains constant: the quality of the PRP matters.

“I’ve spent years educating practitioners on PRP variability and why not all systems produce the same product. The details matter.” – Claudia McGloin

Why Cellenis® Caught Her Attention

Having worked with multiple PRP systems throughout her career, Claudia was particularly interested in the scientific principles behind Cellenis.

Rather than focusing solely on platelet concentration, she looked at the wider factors that influence PRP quality and clinical outcomes. This included platelet preservation, the effectiveness of the separation technology, anticoagulant formulation, product consistency and the ability to achieve reproducible results from treatment to treatment.

These factors all contribute to the quality of the final platelet-rich plasma preparation and can ultimately influence treatment outcomes.

In a field where results can vary significantly depending on the system being used, Claudia believes practitioners need confidence that they are delivering a consistent product every time.

“My expectation was simple: a system grounded in science that could support a more consistent and evidence-based approach to regenerative medicine.”

Supporting a Wide Range of Treatments

At The Regenerative Expert Nurse Clinic, regenerative medicine forms part of a wide range of treatment pathways. Cellenis PRP supports treatments including:

• Facial rejuvenation
• Hair restoration
• Orthopaedic applications
• Intimate wellness
• Menopause-related concerns

According to Claudia, one of the greatest strengths of the system is its versatility.

Rather than viewing PRP as a standalone procedure, she incorporates it into broader treatment plans designed to support tissue repair, restoration and regeneration.

“What Cellenis allows me to do is incorporate the patient’s own biological resources across a wide range of indications while maintaining the same regenerative philosophy throughout the clinic.”

Real Patient Feedback

One patient who had received PRP treatments for more than 14 years using several different PRP systems became one of Claudia’s first Cellenis patients.

The feedback was immediate. At follow-up, the patient reported brighter skin, improved texture and a reduction in the appearance of fine lines around the eyes. Most importantly, she felt the results exceeded those she had experienced with previous PRP systems.

For Claudia, this was particularly significant because the patient had extensive experience of PRP treatments and was uniquely positioned to compare outcomes.

“She told me that, in her opinion, the Cellenis treatment had given her the best result she had seen.”

The Growing Role of Cellenis® DermaFiller

Alongside PRP, Claudia has also seen strong patient interest in Cellenis DermaFiller.

Created from the patient’s own plasma, DermaFiller offers a regenerative option for patients seeking subtle volume restoration while also supporting tissue quality. For many patients, this biological approach is particularly appealing.

“I’ve worked with many PRP kits over the years, and nothing compares to Cellenis. The results I see with Cellenis PRP and DermaFiller are exceptional. My patients love that this is their own body’s filler, made from their own growth factors. They much prefer this to synthetic fillers.”

Patient Perspective

“PRP filler gave me back the structure and strength my skin had lost. It looks firmer, healthier and years younger without looking overdone.” – Margaret, 59

“I didn’t want to look like I’d had ‘work done’ – just fresher. PRP filler was perfect. My skin looks revived, plump and healthy. People say I look well, not different.” – Joanne, 61

Raising Standards Through Education

Beyond clinical outcomes, Claudia believes one of the biggest opportunities within regenerative medicine is education.

Patients are asking more informed questions and practitioners increasingly want to understand not just what a system does, but why it works. As regenerative medicine continues to develop, she believes greater understanding will help raise standards across the sector.

“I would encourage practitioners to look beyond the marketing and really understand how a system works. Ask questions, review the evidence, undertake training and understand why one system may differ from another.”

For practitioners considering PRP, her advice is straightforward: invest in education first, understand the science, focus on quality and never stop learning.

About Claudia McGloin RGN

Claudia McGloin is an internationally recognised Regenerative Medicine Expert, Orthopaedic Nurse Practitioner and one of Ireland’s leading authorities on Platelet-Rich Plasma therapy.

With more than 28 years of nursing experience and over 16 years specialising in regenerative medicine and aesthetics, she is an international speaker, educator, author and Key Opinion Leader for Cellenis.

She is Clinical Director of The Regenerative Expert Nurse Clinic in Sligo, Ireland, where she provides regenerative treatments across aesthetics, orthopaedics, hair restoration, intimate wellness and women’s health.

Why Aesthetic Medical Partnership?

We bring together evidence-based technologies and in-clinic support to help you build treatment protocols tailored for the modern aesthetic patient. By working with AMP, clinics gain not just a supplier, but a committed partner in long-term growth. Partner with us today to transform your practice and elevate your patient outcomes.

A Partnership Built on Shared Values

Claudia’s relationship with AMP UK extends beyond products. She describes the partnership as being built around a shared interest in education, patient safety and helping practitioners make informed decisions about regenerative treatments.

Rather than focusing solely on product supply, the relationship has centred on discussion, training, evidence and professional development.

“What appealed to me about AMP UK was that our conversations were never just about products. We talked about the science behind PRP, patient safety, education, standardisation and some of the challenges facing regenerative medicine as a speciality.”

She continues: “For me, the best partnerships are built on shared values.”

Martyn Roe, Director of AMP UK, added: “We are delighted to be working with Claudia. Few practitioners can match the breadth of her experience in regenerative medicine and PRP. Having lectured internationally and worked with a wide range of PRP systems over many years, her insights are grounded in extensive clinical experience rather than marketing claims.”

“That perspective makes her assessment of different technologies particularly valuable. Claudia understands the strengths and limitations of PRP systems because she has used them in practice, across a broad range of indications and patient groups. Her decision to incorporate Cellenis PRP into her clinic reflects many of the qualities that attracted us to the technology in the first place, including its ability to deliver highly concentrated platelets while minimising red blood cells and inflammatory aspects of white blood cells.”

“We are also excited to be developing an educational programme with Claudia in the coming months, providing practitioners with opportunities to learn from her extensive clinical knowledge and real-world experience of regenerative medicine. Watch this space.”

Looking Ahead

Claudia believes patient expectations are changing. Increasingly, patients are looking for treatments that work with their body’s own biology rather than simply masking signs of ageing.

As awareness of regenerative medicine continues to grow, she expects demand for evidence-based treatments such as PRP and biological fillers to increase. For clinics looking to embrace this shift, she believes systems that prioritise product quality, reproducibility and clinical confidence will play an increasingly important role.

“For me, Cellenis represents more than a PRP system. It reflects the direction regenerative medicine needs to take – with greater emphasis on quality, consistency, education and patient outcomes.”

Contact Us Today

Visit: www.amp-uk.co.uk

Call: 01727 482 432

Email: info@amp-uk.co.uk

WhatsApp: 07771 131 900

The post Why One of Ireland’s Leading Regenerative Medicine Experts Chooses Cellenis® appeared first on Aesthetic Medical Partnership.

But the same device that performs predictably on lighter skin can behave very differently on Fitzpatrick IV to VI. Treating darker skin well is not about doing less; it is about doing it differently, with a clear understanding of the underlying physics and a disciplined, evidence-led approach.

This guide sets out the principles practitioners need to select devices and wavelengths confidently, and to raise the standard of care for every patient who walks through the door.

Why Darker Skin Needs a Different Approach

The defining feature of darker skin, clinically, is increased epidermal melanin, alongside more reactive melanocytes and fibroblasts. For energy-based devices, melanin is a competing chromophore: it absorbs light and laser energy that is intended for another target, such as the hair follicle, a vascular lesion or water in the dermis. When that absorbed energy is concentrated in the epidermis, it generates unwanted heat where you least want it.

The clinical consequences are well documented. Compared with lighter skin, darker skin carries a greater risk of dyspigmentation and scarring, and individuals with Fitzpatrick IV to VI are more prone to prolonged erythema, pigmentary change and scarring following treatment. Post-inflammatory hyperpigmentation (PIH) is the complication practitioners encounter most, and it can be slow to resolve and distressing for patients.

It is worth distinguishing epidermal PIH, which is more superficial and generally more responsive, from dermal pigment, which sits deeper and clears more slowly. This distinction should inform both the modality you choose and the timeline you discuss with the patient.

None of this contraindicates treatment. It simply means device selection, parameters and protocol all have to work harder to protect the epidermis.

Assessing the Patient: Fitzpatrick and Beyond

Patient selection is your first and most important safety control. The Fitzpatrick scale remains the standard starting point, but treat it as a starting point rather than a full picture. It relies partly on self-reported burning and tanning history; it can under-classify constitutive pigment in some patients, and a recent tan can shift facultative melanin well above someone’s baseline. Objective skin-typing tools, including melanin-reading diagnostics built into modern platforms, can support a more reliable assessment and remove some of the guesswork.

A thorough history matters as much as the type itself. Ask specifically about previous PIH or a tendency to mark after minor trauma, any history of keloid or hypertrophic scarring, recent or planned sun exposure, and photosensitising medication.

Establish what the patient has had done before and how their skin responded. Set expectations early: for darker skin, conservative, staged treatment is typically the safest route to a good result, and that conversation is easier before the first session than after a complication.

Principles of Wavelength and Device Selection

The governing principle is straightforward. Longer wavelengths penetrate more deeply and are less readily absorbed by epidermal melanin, so they tend to spare the epidermis. This is why the long-pulsed 1064nm Nd:YAG is widely regarded as the gold standard for laser hair removal in darker skin. At the other end of the scale, fully ablative resurfacing is generally avoided in darker skin because of the pigmentary risk, while non-ablative modalities are preferred for their faster recovery and lower adverse-event profile.

Non-ablative fractional resurfacing is one area where the evidence has matured considerably. The wavelengths used by MultiFrax (1550nm erbium glass and 1927nm thulium) are precisely those studied most in darker skin.

A 2026 review of the dual 1550nm/1927nm fractional system in skin of colour (Fitzpatrick III to VI) reported consistent improvement across studies, though PIH rates varied between them. The wider evidence base consistently links lower energy and density, fewer passes and integrated cooling to a reduced risk of PIH.

Separately, the 1550nm wavelength has shown safety and efficacy for acne scarring in types IV to VI, with the important caveat that self-limited PIH was more common at higher densities. Low-energy, low-density 1927nm has been used to improve existing PIH in darker skin.

The clinical message is consistent: the technology can serve darker skin well when it is used conservatively. For depth on how the two wavelengths work, see our existing MultiFrax wavelength article.

Intense pulsed light demands the most caution. Because IPL delivers a broad spectrum of light, including shorter wavelengths that melanin absorbs strongly, the competition between epidermal pigment and the intended target is at its greatest.

Robust contact cooling, appropriate cut-off filtering and careful parameter control all make a meaningful difference, and the Alpha diode laser and 3D IPL system is built around those controls exactly. Even so, they do not remove the need for rigorous patient selection. IPL should be approached conservatively in Fitzpatrick IV, with particular care as you move towards V and VI, and always guided by the device instructions for use.

Safer-Practice Settings and Protocols (Principles, Not Parameters)

Exact fluences, densities and pulse settings belong in the device IFU (Instructions for Use) and in hands-on training, and they vary by platform, indication and individual patient. What does generalise is the set of principles that reduce risk.

Published guidance for energy-based treatment in darker skin consistently points to longer wavelengths, the minimum effective fluence, lower density, fewer passes, appropriate cooling and longer intervals between sessions.

In practice, that means starting conservatively and building gradually rather than chasing a result in a single aggressive session. A test patch in a representative but discreet area is good practice in higher Fitzpatrick types. Reviewed after an appropriate interval before you commit to a full treatment, it helps you read how an individual’s skin responds.

Allow generous healing time between sessions, keep cooling consistent throughout treatment, and document settings and results so each session informs the next. Treat to a conservative clinical endpoint rather than the most visible immediate reaction, and stop sooner rather than later if the skin response exceeds what you expected. When the device IFU and your training conflict with what feels commercially tempting, follow the IFU.

Reducing the Risk of PIH Before and After Treatment

Much of the work that prevents PIH happens around the treatment rather than during it. Before treatment, strict photoprotection is non-negotiable: broad-spectrum, high-SPF sunscreen, ideally with iron oxides for additional visible-light protection. The patient should also avoid treatment if their skin has recently tanned, since prior sun exposure and epidermal disruption both worsen PIH risk.

Where clinically appropriate and under the relevant prescriber’s direction, priming the skin with topical agents such as retinoids or depigmenting preparations may help. This is a decision for the treating clinician within prescribing rules rather than a blanket recommendation.

Afterwards, gentle aftercare, continued cooling and disciplined sun avoidance support recovery and limit reactive pigmentation. Expectation-setting is part of risk management, too. Outcomes in darker skin are often achieved over a course of treatments rather than in one. Improvement is gradual, and conditions such as melasma are prone to recurrence and are typically managed alongside topical therapy. Framing the goal as a visible improvement, maintained over time, rather than a one-off “fix”, protects both the patient and the clinic.

When to Proceed With Caution or Refer

Some presentations call for a pause. A history of keloid or hypertrophic scarring, a recent tan, recent isotretinoin use, active or unstable inflammatory skin disease, photosensitising medication, or unrealistic expectations should all prompt a more cautious plan or a deferral.

Any pigmented lesion where the diagnosis is not clear belongs with a dermatologist before any energy is applied, not in a cosmetic treatment chair. The most experienced practitioners are comfortable saying “not today” or “not with this device”, and that conservative judgement is itself a marker of a high-standard clinic.

Building Confidence in Your Team

Safe, confident treatment of darker skin is a capability you build, not a setting you select. It comes from understanding the science, knowing your device’s IFU thoroughly, and having protocols and patient-selection guidance you can rely on. This is where the right supplier relationship earns its keep.

We support partner clinics with hands-on training, treatment protocols and patient-selection guidance, backed by a clinical and KOL (Key Opinion Leader) network. This is so your team can offer treatments across diverse skin types with genuine confidence rather than caution born of uncertainty. Investing in that knowledge is what turns a capable device into a reliably safe service.

Talk to AMP About Treating Diverse Skin Types

If you are selecting or expanding energy-based capability and want it to serve every patient safely, we can help you match the right device and training to your clinic. Explore the full medical aesthetic device range, or get in touch to discuss device selection and training for Fitzpatrick IV to VI.

FAQs

Is laser treatment safe for darker skin types?

Yes, when the device, wavelength, settings and protocol are chosen appropriately. Modern non-ablative and longer-wavelength technologies have a well-established safety record in Fitzpatrick IV to VI, but darker skin carries a higher risk of post-inflammatory hyperpigmentation, so conservative settings, careful patient selection and proper cooling are essential. Exact parameters should always follow the device instructions for use and accredited training.

Which wavelengths are safer for darker skin?

As a general principle, longer wavelengths are safer because they penetrate more deeply and are less absorbed by melanin in the epidermis. The 1064nm Nd:YAG is widely considered the gold standard for hair removal in darker skin, and non-ablative fractional wavelengths such as 1550nm and 1927nm have a strong evidence base for resurfacing and pigmentation when used at conservative energy and density.

How can clinics reduce the risk of PIH in darker skin?

Before treatment, use strict photoprotection and avoid treating recently tanned skin. During treatment, favour longer wavelengths, the minimum effective fluence, lower density, fewer passes and consistent cooling, with longer intervals between sessions. Afterwards, support recovery with gentle aftercare and sun avoidance. A test patch in higher Fitzpatrick types helps gauge individual response before a full treatment.

Can IPL be used on Fitzpatrick IV to VI?

IPL requires the most caution of any light-based modality in darker skin because its broad spectrum is strongly absorbed by epidermal melanin, raising the risk of burns and pigmentary change. It can have a role in carefully selected patients when delivered with appropriate filtering, robust cooling and conservative settings, with the greatest care as skin type increases towards VI. Rigorous patient selection and the device instructions for use should always guide the decision.

What should practitioners assess before treating darker skin?

Start with Fitzpatrick type, but go further: assess constitutive pigment objectively where possible, take a history of PIH and keloid or hypertrophic scarring, check for recent sun exposure or tanning, review photosensitising medication, and understand previous treatment responses. Set realistic expectations about staged treatment and recurrence, and refer any pigmented lesion of uncertain diagnosis for dermatological review before treatment.

The post Treating Darker Skin Safely: Device and Wavelength Selection for Fitzpatrick IV to VI appeared first on Aesthetic Medical Partnership.

Their issues do not align neatly with age-segmented categories. A patient in her early fifties may have skin laxity, a softening jawline, loss of tone across the arms and abdomen, and shifting pigmentation, all at once and within a relatively short window.

Treated as separate complaints, the picture becomes a series of disconnected appointments. Treated as what it actually is, a single physiological transition with predictable features, it becomes a clinical pathway.

This is an underserved commercial position. The menopause demographic is sizeable, increasing, and notably loyal once a clinic demonstrates that it understands the underlying physiology rather than selling against the symptoms.

This article presents a four-pillar pathway framework for clinics treating the menopause demographic in 2026, built around devices that can address skin and muscle in the same protocol.

What Happens to Skin During Menopause?

The changes seen in menopausal patients are not simply accelerated chronological ageing. They form a specific physiological cluster driven by declining oestrogen, and understanding that cluster is what separates a targeted pathway from a generic anti-ageing offer.

Collagen and Muscle: The Structural Drop

The foundational work by Brincat and colleagues on post-menopausal skin reported an average decline of around 1 to 2 per cent per year in dermal collagen content.

Running in parallel is a loss of lean muscle mass. Published data described a lean body mass decline of approximately 0.5 per cent per year during the menopausal stage, alongside a 1.7 per cent annual increase in fat mass, with the rate of muscle loss accelerating in the years that follow.

Muscle provides the scaffolding beneath soft tissue, so its atrophy produces a change in contour and support that no skin-surface treatment can fully address.

Barrier, Fat Redistribution and Pigment

Alongside these structural changes, barrier function reduces, leaving skin drier and more reactive; fat redistributes, often centrally; and hormonally influenced pigmentation becomes more prominent. Menopause is a whole-body endocrine transition.

Why Generic Anti-Ageing Protocols Underserve Menopausal Patients

Most clinic menus were built around individual concerns, not a physiological transition. That is where they fall short.

Injectables remain excellent at what they do, but address neither collagen architecture across a region nor underlying muscle tone. Surface radiofrequency improves skin quality and can stimulate dermal collagen, but operates at the level of the skin; it does not reach muscle.

For a patient whose contour change is substantially driven by muscle atrophy, surface RF alone treats one layer of a two-layer problem. Standard body contouring has the inverse limitation, improving fat or muscle parameters while ignoring the skin quality that menopausal patients are often most distressed by.

The menopausal patient lives the physiology daily and can tell when a clinic has or has not understood it.

Menopausal Concern × Modality Matrix

Which Aesthetic Treatments Work Best for Perimenopause? A Four-Pillar Pathway

A pathway matching the physiology needs to address four distinct layers, overlapping in delivery but sequential in logic.

Pillar One: Skin Quality and Barrier

The foundation is barrier function and hydration, both compromised by declining oestrogen. Addressing this first increases the skin’s tolerance of subsequent treatments and gives an early, visible result. Aquafirme XS supports hydration and barrier conditioning as a preparatory and maintenance layer; EXO|E functions as a regenerative topical and post-treatment barrier support, settling the skin after energy-based work.

Pillar Two: Collagen Architecture

This is where the steep post-menopausal collagen decline is directly addressed, and the contrast between dual-action and surface-only RF becomes clinically meaningful. The goal is to address collagen and the muscle layer beneath it as part of one architectural strategy, rather than treating the dermis in isolation and leaving the structural layer for a separate conversation.

Pillar Three: Muscle Tone Restoration

This is the layer most pathways leave out, and the one the physiology makes unavoidable. A pathway that ignores muscle is incomplete by design.

Stim Prime is the natural anchor: its Diatermocontraction technology delivers radiofrequency and electromuscular stimulation in a single combined signal, so collagen stimulation and muscle activation are addressed in the same session. The bQuad facial applicator covers the jawline, neck and décolleté; Thermosculpt and biQuad+ extend the same mechanism across body areas. Jovena FaceStim runs on the same Diatermocontraction technology, so clinics focused solely on facial treatment get the identical collagen-and-muscle mechanism in a single-area platform.

For a demographic whose defining feature is that skin and muscle change simultaneously, a modality that treats them together is a closer match to the underlying biology.

Pillar Four: Body Composition and Contour

The final pillar addresses fat redistribution and loss of contour. Thermosculpt suits the central distribution changes common in this demographic; biQuad+ addresses arms, flanks and other irregular contours.

Because Stim Prime carries both face and body applicators, the body pillar runs on the same platform as the collagen and muscle work.

Why Face and Body Both Matter for This Demographic

Menopausal patients very commonly describe their experience in whole-body terms. A clinic that can only address the face, or only the body, is structurally unable to present a complete answer, no matter how good the individual treatment is. The patient completes the part that the clinic can offer and goes elsewhere for the rest.

Comprehensive pathways retain patients. A device such as Stim Prime, carrying both face and body applicators, lets a single clinic deliver the entire pathway.

For clinics with a more contained need, the sister devices BodyStim and Jovena FaceStim address body and face, respectively, as single-area options. Jovena FaceStim delivers the same Diatermocontraction mechanism as Stim Prime, so the collagen and muscle benefits carry across to the facial-only platform.

Designing the Consultation

Hormonal status should be discussed in the clinical context: whether a patient is perimenopausal or post-menopausal affects the trajectory of her skin and muscle changes and, therefore, the framing of the pathway.

HRT context is relevant at a category level because it provides background for setting expectations; decisions about hormone therapy sit with the patient’s medical practitioner.

A realistic 12-month horizon is usually the right frame, since this is a transition managed over time rather than a single procedure with a fixed endpoint. Where applicable, alignment with the patient’s primary care provider or menopause clinic is good practice.

Photographic standards should be consistent, because a 12-month pathway relies on demonstrating change reliably.

Commercial Considerations

Retention tends to be high because a patient who feels understood does not readily switch. Referral patterns are strong because this demographic talks to peers going through the same transition. Patient lifetime value is correspondingly high.

Course-based pricing models suit the pathway structure: a pathway delivered over 12 months across four pillars lends itself to a course rather than a sequence of one-off transactions, aligning the clinic’s commercial interest with the patient’s clinical result.

The Body Treatment Opportunity sets out the wider revenue case for clinics adding non-invasive body work.

All menopause-related marketing must remain CAP compliant: claims should be substantiated and proportionate, hormone therapy should be discussed only at a category level rather than by naming specific products (as required by CAP rule 12.12), and results claims should reflect what the evidence supports.

Reframing the Pathway

The menopausal patient is not presenting a deficit to be corrected. She is presenting a physiological change with a predictable, well-documented set of features.

The reason generic anti-ageing menus underserve her is not that the individual treatments are poor, but that the menu was never designed around the shift.

A four-pillar approach organises the clinic’s response around the physiology rather than the menu.

Delivered on a face-and-body-capable platform, with Diatermocontraction addressing collagen and muscle in a single signal, it allows a clinic to present one comprehensive plan to a patient who has, until now, mostly been offered fragments.

To walk through how Stim Prime fits into a menopause pathway in your clinic, book a Stim Prime consultation with the AMP clinical team.

Frequently Asked Questions

What happens to skin during menopause?

Declining oestrogen drives a range of changes. Skin collagen decreases substantially in the early post-menopausal years. Lean muscle mass declines at an accelerating rate, barrier function reduces, fat redistributes centrally, and hormonal pigmentation becomes more prominent. It is a distinct multi-system transition, not just older skin.

How does Stim Prime treat menopausal skin and muscle changes?

Stim Prime uses Diatermocontraction, delivering radiofrequency and electromuscular stimulation in a single combined signal. It treats dermal collagen and the underlying muscle in the same session, matching a physiology where skin and muscle change at the same time. Its face and body applicators let one platform deliver the collagen, muscle and contour pillars.

Which aesthetic treatments work best for perimenopause?

A structured four-pillar pathway rather than a single treatment: skin quality and barrier, collagen architecture, muscle tone restoration, and body composition and contour. For a transition defined by simultaneous skin and muscle change, a dual-action RF and EMS approach can match the physiology better than injectables or surface RF alone.

The post The Menopause Patient: Building an Aesthetic Treatment Pathway for Hormonal Skin and Body Change appeared first on Aesthetic Medical Partnership.

Despite this, the majority of cases are still detected at a late stage. Late-stage diagnosis remains the single most significant determinant of survival outcome.

Visual examination is, and will remain, the key to oral cancer screening in dental practice. But visual examination alone has well-documented limitations. New chairside diagnostic technologies are changing the way frontline dental teams handle suspicious or ambiguous findings.

This article discusses what salivary biomarker testing actually does, where it fits in the clinical workflow, and what practices should consider before implementing it.

To be clear from the outset: this is not a replacement for visual examination. It is a clinical decision support tool that adds objective molecular data to the clinical picture. How regularly a practice uses it is a clinical decision: some will reserve it for suspicious or ambiguous findings, while others will screen higher-risk groups routinely.

The Current State of UK Oral Cancer Detection

Oral cancer is among the most preventable cancers when identified early, yet the UK’s detection record remains poor. According to the Oral Health Foundation’s State of Mouth Cancer UK Report, more than 8,800 new cases of oral cancer were diagnosed in the UK in 2021, which is an increase of 34% over the previous decade.

It’s more than double the number recorded twenty years earlier. By 2024, the Oral Health Foundation reported that UK cases had surpassed 10,000 for the first time.

The consequences of late detection are severe. Cancer Research UK’s survival data shows five-year survival exceeding 85% at stage I, falling to just 35% at stage IV. The survival difference between early and late presentation is one of the most pronounced in oncology. The Mouth Cancer Foundation reports that mouth cancer now causes more deaths in the UK each year than cervical and testicular cancer combined, accounting for over 3,600 lives lost annually.

Dental teams are crucial in this scenario. Most patients see their dentist more frequently than their GP, and the oral cavity is directly accessible during routine examinations.

Yet the referral-to-diagnosis pathway remains imperfect, partly because visual examination (for all its value) introduces variability that clinical training alone cannot fully resolve.

Where Visual Examination Has Limits

Visual and tactile examination of the oral mucosa is the standard of care, and nothing in this article argues otherwise. Experienced clinicians perform it well, and it accurately detects the majority of clinically evident lesions. The question is what happens at the margins, and the margins matter.

The Problem of Subtle and Early-Stage Lesions

Subtle early lesions may appear as unremarkable mucosal changes. A small area of erythroplakia or a mildly irregular white patch may look similar to trauma, ulceration from a denture, or simple irritation. In the absence of a clear visual alarm sign, clinical judgement is left to carry a significant diagnostic burden.

Certain anatomical sites compound this further: the posterior tongue, floor of the mouth, soft palate, and oropharynx are all areas where early lesions can be difficult to visualise completely, especially in patients with a strong gag reflex or limited mouth opening.

Variability Between Practitioners

There is also the inherent subjectivity of clinical interpretation. Research published in peer-reviewed literature has found significant variation between general dental practitioners and specialists in correctly identifying potentially malignant oral disorders, with awareness and diagnostic accuracy consistently lower among GDPs than among specialists.

This is not a criticism of the profession; it reflects the diagnostic complexity of early-stage oral mucosal disease. Adjunctive testing exists precisely to provide objective data where subjective interpretation reaches its limits.

How Salivary Biomarker Testing Works

The biological basis for salivary biomarker testing is well established. When oral mucosal cells undergo malignant transformation, certain protein-based markers become overexpressed and detectable in saliva. The BeVigilant™ OraFusion™ system targets two of these: p16 and EGFR.

p16 (CDKN2A) is a tumour suppressor protein that regulates the cell cycle, and altered expression is associated with dysplastic and malignant oral epithelial change.

EGFR (epidermal growth factor receptor) is a cell surface protein whose overexpression is linked to tumour development and progression in oral squamous cell carcinoma. Measuring both markers together provides complementary signals of abnormal cellular activity rather than relying on a single biomarker in isolation.

The Chairside Process

A small saliva sample is collected using the single-use Ora-3D collection device, which requires no needles and no tissue disruption. The sample is applied to the Ora-3D test cassette and inserted into the BeVigilant Reader, which uses a lateral flow immunoassay to generate quantitative biomarker signal intensities.

These are combined with the patient’s clinical risk profile (age, sex, tobacco use, alcohol use, and lesion features) using a unique sensor fusion algorithm. The system has been shown to achieve over 93% accuracy in detecting these biomarkers.

The output, delivered in roughly 15 minutes, is a binary classification: Monitor or Investigate Further. OraFusion is a pre-diagnostic risk stratification tool, not a diagnostic test. A result of “Investigate Further” indicates that the combination of biomarker data and clinical risk factors warrants specialist referral and further evaluation, including biopsy where necessary. It adds objective molecular data to the existing clinical picture; it does not replace it.

Where it Fits in Clinical Workflow

OraFusion is appropriate when visual examination yields a suspicious or ambiguous finding, and the clinician wants objective data to support a referral decision. This is the primary use case, where clinical uncertainty is highest, and the benefit of additional data is greatest.

It is also appropriate for higher-risk patients presenting for routine examination: those who are or have been heavy smokers, consume alcohol heavily, have a history of HPV exposure, or have previously been treated for oral cancer. As the recognised risk-factor profile continues to broaden, some practices will choose to screen defined cohorts on a regular basis, for example, patients over a certain age or those with known lifestyle risk, rather than testing only in response to a specific finding.

It is also suitable when a borderline lesion makes it difficult to decide between “watch and wait” and “refer now.” An objective result can provide a clear clinical rationale for the chosen pathway.

Where it May Not Be Appropriate

OraFusion is not a substitute for visual examination, nor a means of avoiding specialist referral, and a positive result still requires that pathway. The system generates data that the clinician integrates with all of the other information they have about the patient. How regularly a practice screens, and which patient groups it screens, are clinical decisions; what matters is that the result informs the pathway rather than replacing clinical judgement.

There are also specific contraindications to testing: patients with an active oral infection, significant oral bleeding, or recent oral surgery within the preceding ten days are not suitable candidates, as these factors can affect the reliability of results. Patients should also be advised to have nothing by mouth for one hour before the test, including water, food, coffee, and tea. This is most practically communicated at the point of booking or in the pre-appointment reminder.

Professor Bob Khanna’s webinar on rapid chairside oral cancer screening covers the clinical application of OraFusion in considerable practical detail, including how the system integrates with appointment workflows and how to approach patient communication. For dental teams considering whether and how to implement the technology, it is the most useful single resource available.

Regulatory Status and Clinical Evidence

OraFusion carries CE marking and received IVDR approval in September 2025. In the United States, it holds an FDA Breakthrough Device designation, awarded in April 2023. This is a programme designed to expedite the development and review of devices intended to provide more effective diagnosis or treatment of life-threatening conditions than currently available alternatives.

The system is in clinical use across the UK, Germany, Italy, and other European markets. A pivotal multi-site clinical trial is in progress with FDA alignment confirmed as of September 2025.

Practical Considerations for the Practice

Patient communication requires the most care. Introducing biomarker testing to a patient with an uncertain finding means framing it clearly: this is a structured step to determine the most appropriate next action, not a test that confirms cancer. Practices that establish consistent communication protocols for this will see better clinical and patient experience outcomes.

Workflow and Training

Workflow integration is straightforward. The 15-minute test runs alongside other appointment activity with no external laboratory required, which makes it ideal for clinics that already have tight deadlines for urgent referrals.

The device guides the operator through the process at each step, making it straightforward to delegate to a dental nurse, hygienist, or therapist. Practices should ensure that whoever is performing the test is clear on the contraindications and pre-test patient preparation requirements to avoid unreliable results.

Offering a structured oral cancer risk assessment service has significant reputational value for practices that focus on cancer detection and prevention. Unlike many practice differentiators, this one has clinical substance behind it.

Conclusion

The dental teams that use OraFusion effectively are those who treat it as a considered input in a clinical decision-making process, deploying it in the right cases and interpreting it alongside everything else known about the patient.

Oral cancer survival is heavily determined by stage at diagnosis. For practices considering whether adjunctive salivary biomarker testing belongs in their toolkit, the clinical case for earlier, more confident detection is clear. The question is how to integrate it in a genuinely beneficial way rather than simply procedurally.

For technical details on the BeVigilant™ OraFusion™ system, visit the OraFusion product page. For a more in-depth clinical explanation, Professor Bob Khanna’s webinar is the recommended next step. To explore whether OraFusion is right for your practice, get in touch with AMP to arrange a demonstration.

The post Chairside Oral Cancer Screening: What Salivary Biomarker Testing Offers UK Dental Practices appeared first on Aesthetic Medical Partnership.

Aesthetic clinics are seeing more enquiries from patients who don’t want a full surgical facelift but want more than what injectables alone can provide. And, they’re arriving with a vocabulary that mixes “non-surgical facelift”, “lifting threads” and “endolifting” into one general expectation that something can be done.

Most clinic owners respond by asking which technology is best for facial lifting. That’s the wrong question. The three pathways available aren’t direct competitors. They sit on a scale of invasiveness, downtime, longevity and cost, and the strongest aesthetic clinics tend to offer two of the three, often in combination, with a clear referral relationship for the third.

The question is which pathway is right for your clinic. This article works through that decision: what each pathway actually is, who it’s for, what it asks of your clinic operationally, and how to choose the one that fits the practice you’ve already built.

The Three Pathways at a Glance

Before comparing them, it’s worth understanding what each pathway actually involves, because the language in the market often blurs the differences.

RF Endolifting

Radiofrequency energy is delivered into the subdermal layers via a micro-cannula. It’s minimally invasive, typically performed under local anaesthetic, and depending on the device and protocol, often completed in a single session.

Treatments such as InLift by ThermaDAS sit within this category. Results typically develop over weeks as collagen remodels, with published evidence supporting efficacy in mild to moderate laxity. The treatment targets the jawline, midface and perioral areas, the zones where structural laxity tends to present earliest and where patients are most resistant to surgical intervention.

It’s worth distinguishing RF endolifting from laser endolifting, because the two are often spoken about interchangeably, but the clinical and commercial implications are different. Both use a subdermal micro-cannula delivery method, but the energy source isn’t the same. Laser endolifting (typically a diode fibre, often 1470nm) produces a more aggressive heating profile than the radiofrequency devices.

Laser endolifting carries a higher burn risk because the temperature is harder to control. The laser delivering optical fibre is also fragile, and reports of it snapping when treating a fibrous tissue area (such as when a patient has had HIFU or Sculptra) are common. Consumable costs are also high, and, as such, patient costs tend to be higher.

RF endolifting occupies a different commercial position: more controlled energy delivery, a lower complication profile, and a price point that suits the laxity patient who isn’t ready for the cost or downtime of a more aggressive intervention.

Thread Lifts

Absorbable PDO or PCL threads are inserted under the skin via cannula, providing immediate mechanical lift and longer-term collagen stimulation as the threads dissolve. Thread lifts are minimally invasive, require only local anaesthetic, and the results are visible immediately.

Published multicentre data puts typical longevity at around 6–12 months, depending on thread material, with PDO degrading sooner than PCL. They are best suited to moderate laxity where mechanical repositioning is needed rather than gradual tightening.

Surgical Lifting

This is the traditional facelift, neck lift or mini-lift performed under general or local anaesthetic in a surgical setting. It is the most significant intervention, with the most dramatic and longest-lasting results. It is best suited to substantial laxity beyond what minimally invasive options can address.

Each pathway has a distinct patient profile. The rest of this article is about matching the pathway to the patient and to the clinic.

Patient Suitability

RF endolifting is often suitable for patients aged 35 to 55 with mild to moderate laxity who want subtle but meaningful improvement without downtime. Often, these are patients who have tried injectables and want to address structural laxity that filler alone can’t fix. This may be for a softening jawline, early jowling or perioral laxity in patients who aren’t ready to consider anything more invasive.

Thread lifts often suit patients with moderate laxity, more commonly seen from the early forties onwards. They want an immediate, visible lift and will accept some downtime, along with the small risk of palpability or asymmetry.

They’re useful for patients who need more lift than energy-based devices can deliver but who aren’t candidates for surgery, or simply aren’t interested in it.

Surgical lifting is typically appropriate for patients with significant laxity, often aged 50 and above, where mechanical repositioning of underlying structures is required to achieve the desired result. The patient profile here is substantially different. The conversation is more about anatomical change, not skin quality.

The honest framing: a patient walking through your door asking about “facelift alternatives” could be a candidate for any of the three. The skill is in the consultation, not the device. A clinic that can effectively assess all three categories, even if it only offers one or two in-house, will retain patients and build referral trust in a way that single-pathway clinics rarely manage.

Patient suitability, however, is only half the picture. The other half is whether your clinic can actually deliver the pathway well, and the operational gap between the three is wider than the clinical gap.

What Each Pathway Asks of Your Clinic

The three pathways diverge most sharply in terms of operational and commercial demand, and this is where the realistic options narrow for most practices.

RF Endolifting: Capital Investment, Premium Positioning

A device purchase with a higher per-treatment fee and premium positioning. Practitioner training varies by manufacturer but is typically a short, structured programme for the device itself, though real consultation expertise takes longer.

The pathway needs a single treatment room, no surgical permissions, and consumables are manageable.

Volume is lower than for injectables, but revenue per session is higher, and repeat visits are common. Jawline patients often return for neck or perioral work. It fits neatly into an existing aesthetic clinic without major operational changes. That’s part of why it has gained credibility with medical and dental clinics expanding into aesthetics, and why it suits practices whose brand already relies on technology investment.

Thread Lifts: Lower Capital, Higher Clinical Demand

The spend sits in per-treatment consumables rather than device investment, with a moderate fee often booked in series. Clinically more demanding: requires a medical practitioner trained in injection technique and complication management, comfortable handling bruising, asymmetry and the occasional thread palpability follow-up.

The complication profile is higher than that of energy-based options, with implications for insurance and medical director oversight. Volume potential is higher than for RF endolifting, but the market is more competitive, and consumables erode margin. A strong fit for clinics with high injectable volume already, where the patient base is conditioned to repeat treatment cycles and the practitioner team is comfortable with cannula work.

Surgical Lifting: A Referral Relationship, not an In-Clinic Offering

Theatre, anaesthetist and a full surgical process. Requires a plastic surgeon or facial plastic surgeon, which is why almost no aesthetic clinics offer this in-house. The pathway often reaches the clinic as a referral fee or partnership arrangement, with the highest revenue per patient, but a long sales cycle and low volume.

Useful as a credibility piece and a service to patients who truly need it, but rarely a commercial driver. Clinics that handle this well treat the referral itself as part of their offering rather than a loss of revenue.

Where Stacking Pathways Beats Choosing One

Some of the strongest clinical results come from combining pathways. The most common pairing in aesthetics is RF endolifting with thread lifts, performed either in the same session or in a planned two-stage protocol.

Threads deliver an immediate visible lift through mechanical repositioning of soft tissue. RF endolifting works on a different timeline, gradually tightening the subdermal layer through collagen remodelling over weeks. Used together, the two give the patient a visible result on day one, and they continue to improve as the RF effect develops.

The combination also addresses something neither pathway does well in isolation: threads lift but don’t meaningfully improve skin quality or reinforce the structural scaffold that holds them, and RF tightens but doesn’t reposition tissue that has already descended.

The patients who benefit most have moderate laxity and are in their early forties to early fifties. For them, threads alone would lift but leave skin quality untouched, while RF alone would tighten but do little for visible descent.

It’s also a strong fit for patients whose laxity sits in the grey zone between minimally invasive and surgical candidacy, and for those who want a single considered intervention rather than repeat treatment cycles.

How to Decide What Fits Your Clinic

Three questions are worth answering honestly before committing to a pathway.

What Does Your Existing Patient Base Actually Want?

Pull your last three months of consultation notes and enquiry forms. Count how many patients arrived using thread-related language versus device or “endolift” language. The pathway that matches their existing vocabulary will convert faster than one you have to educate them into, and the data is already in your booking system.

What’s Your Team’s Existing Skill Set?

Be honest about who is going to perform the treatment. If it’s a practitioner who currently spends most of their week on injectables, threads will likely integrate within weeks. If it’s a practitioner already operating energy-based devices, RF endolifting will slot in just as quickly.

Choosing the pathway that demands the steeper learning curve usually means a longer ramp to profitability and a higher rate of treatment-room hesitation in the first six months.

What’s Your Clinic’s Commercial Positioning?

Look at how patients describe your clinic to others. If the recommendation reads as “they have the latest technology”, RF endolifting reinforces that positioning. If it reads as “they’re brilliant with injectables, and you’ll see results immediately”, threads extend it. Choosing the pathway that contradicts your existing brand story is possible but expensive. You’re paying twice: once for the equipment or training, and again to reposition.

Closing

The three pathways aren’t competing technologies. There’s a range of options that can be matched to a patient or combined within a single protocol. The clinics that handle facial lifting best are usually the ones that can honestly assess a patient and recommend the right approach, whether that’s a single pathway, a stacked protocol, or a referral when surgery is the right answer.

If RF endolifting looks like the right fit for your clinic, the natural next step is a closer look at how it sits within the wider skin-tightening category. Our earlier piece, The Clinic Owner’s Guide to Skin Tightening Technology, compares RF, plasma and fractional laser approaches in detail and sets out where InLift ThermaDAS sits within that landscape.

If you’d like to explore how RF endolifting could sit alongside your existing treatment menu, the AMP team can walk you through the clinical and commercial details.

The post RF Endolifting, Thread Lifts or Surgical Lifting: Which Facial Lifting Pathway Fits Your Clinic? appeared first on Aesthetic Medical Partnership.

Many have built successful practices around facial rejuvenation, skin tightening, and injectable treatments, and for good reason. But the market is moving.

Clinics that rely solely on facial treatments are now overlooking one of the most accessible routes to meaningful revenue growth.

A New Category of Patient Demand

Perhaps the most significant driver of body treatment demand in 2025 and 2026 has been the rapid adoption of GLP-1 weight loss medications such as semaglutide and tirzepatide.

According to research published in BMC Medicine, around 1.6 million UK individuals used these medications to support weight loss between early 2024 and early 2025. An additional 3.3 million expressed interest in starting treatment within the next year. The patient pipeline is vast and continues to expand.

Weight Loss Is Only Half the Story

The aesthetic consequences of rapid weight loss are becoming difficult to ignore. A review published in the Journal of Cosmetic Dermatology notes that GLP-1-driven weight loss often results in skin that no longer conforms to the body’s new contours.

These patients look thinner, but they don’t necessarily look toned or feel confident about their shape. This creates a patient who is actively motivated and looking for a non-surgical solution to complete their transformation.

For clinics that can offer targeted body tightening and muscle toning, this is a new demographic walking through the door. The demand isn’t going away.

The Revenue Case for Body Treatments

There is strong commercial logic for adding body treatments to your menu. Body services naturally lend themselves to multiple areas of treatment. A patient who comes in for abdominal toning may also want thigh contouring, glute lifting, or arm tightening. Because of this, body treatments are more easily packaged into treatment courses and have a high average transaction value.

Course-Based Revenue and Operational Efficiency

Body sculpting and toning courses lasting six to eight sessions are common in the category, resulting in predictable, recurring revenue over several weeks. Compared to one-off facial treatments, a body treatment programme often represents a significantly larger per-patient spend. When you factor in the potential for maintenance sessions and cross-referrals into existing facial services, the lifetime value of a body treatment patient can be substantial.

There’s also a practical efficiency benefit. Modern body sculpting platforms like BodyStim are designed to streamline treatment delivery. Built-in pad-placement guidance and real-time thermal sensors enable precise setup and controlled energy delivery, decreasing the complexity of each session.

With dual-subject simultaneous treatment capability, a single device can treat two patients at once, meaning higher revenue per hour from a single piece of equipment compared to procedures that can only serve one patient at a time.

The Timing Advantage

Body treatments in the UK aesthetic market are still in a growth phase. Unlike injectables or skin rejuvenation, where competition is fierce and patient loyalty needs to be earned, body sculpting and toning is a category where many clinics have not yet established a strong position. For facial-focused practices that move now, there is a genuine first-mover advantage in their local market.

Establishing body treatments as part of your clinic’s identity takes time. Patients need to see results from other clients and build confidence in the treatment. Clinics that begin to establish this reputation now will be significantly better positioned when body treatment demand, driven by GLP-1 adoption and broader consumer trends, reaches new heights.

Why Clinics Hesitate When Acquiring New Devices

The most common objection from facial-focused clinics is that body treatments feel like a separate business. The patient demographics seem different, the marketing feels unfamiliar, and the technology requires a new investment. These concerns are understandable, but they are increasingly outdated.

Why the Barriers Are Lower Than You Think

The reality is that most clinics already have the patient base for body treatments. Patients who trust you with their facial aesthetics are ideal candidates for body services. They already have a relationship with your clinic, they are comfortable spending on non-surgical treatments, and many of them are privately wondering whether you offer something for the areas they see in the mirror from the neck down.

Introducing body treatments doesn’t mean building a new audience. It means serving the existing one more completely.

Modern devices fit easily into standard clinic environments and can be operated by existing team members with straightforward onboarding. When acquiring a new device from us, we offer comprehensive training to help you and your team get up to speed as quickly as possible.

While it does require investment, the return timeline for a well-positioned body sculpting device is typically faster than many clinics expect, particularly when treatment courses are sold upfront.

What to Look for in a Body Treatment Platform

Not all body devices are created equal, and clinics entering this space should be discerning about the technology they invest in. The most commercially successful body treatment platforms tend to share a few key characteristics.

Versatility, Efficiency, and Clinical Credibility

A device that only addresses one concern limits your treatment menu and your ability to respond to what patients actually want. The strongest platforms combine muscle stimulation with skin tightening, allowing clinics to address tone, definition, and laxity in a single treatment protocol. This dual action is important for patients losing weight and experiencing muscle loss and skin laxity simultaneously.

Devices that facilitate multi-area or dual-patient treatment allow clinics to maximise throughput without sacrificing results. The ability to treat several body zones in a single session has a direct impact on revenue per hour.

Third is clinical credibility. In an increasingly educated market, patients are doing their research before they book. A body treatment device backed by visible clinical results and a clear mechanism of action provides both the clinic and the patient confidence in the investment.

Where BodyStim Fits

For clinics evaluating their options, BodyStim by Imperium is worth a close look. It combines RF diatermocontraction (a controlled radiofrequency signal that triggers both deep heating and muscle contraction) with neuromuscular stimulation, delivering both skin tightening and muscle toning through a single platform.

Three treatment modes (Thermosculpt™, biQuad+™, and Hybrid) allow practitioners to customise protocols to meet particular patient goals, including deep muscle activation, targeted contour refinement, or a combination of both.

Built for Clinic Profitability

BodyStim supports dual-patient treatment, meaning two people can be treated simultaneously. For busy clinics looking to maximise the commercial return on a single device, this is a significant operational advantage.

Importantly, BodyStim aligns with the specific clinical needs of patients who have recently lost significant weight. Its combination of muscle toning and skin tightening makes it well-suited to the growing number of post-weight-loss patients now seeking non-invasive body treatments.

Take the Next Step

If you’re thinking about whether body treatments are a good fit for your clinic, we’d love to talk.

We work with clinics across the UK to identify the right technology for their goals and growth stage. Whether you’re starting from scratch with body services or looking to upgrade from a basic platform, our team can help you model the revenue potential and find the right fit.

Get in touch with our team to book a BodyStim demonstration or discuss how body treatments could fit into your clinic’s growth strategy.

The post The Body Treatment Opportunity: Why Facial-Only Clinics Are Leaving Revenue on the Table appeared first on Aesthetic Medical Partnership.

By combining key biomarkers with individual patient risk factors, the system helps clinicians move beyond visual assessment alone when faced with uncertainty. Alongside the clinical insight, the session also covers the practical considerations of introducing structured oral cancer screening into a modern dental practice – including how it can fit within the patient journey and support the development of additional clinical services.

The post Rapid Chairside Oral Cancer Screening | Prof. Bob Khanna appeared first on Aesthetic Medical Partnership.

Led by Dr Sary Kadar, Medical Director of Estar Medical and a recognised expert in autologous regenerative therapies, this webinar combines clinical insight with hands-on experience. With a strong focus on PRP applications across dermatology, skin rejuvenation and hair restoration, it offers valuable guidance for practitioners looking to deliver more predictable, natural-looking results.

The post Cellenis PRP for Hair Restoration Webinar | Dr Sary Kadar appeared first on Aesthetic Medical Partnership.

Developed by Solta Medical (now part of Bausch Health), the Fraxel Dual set the benchmark for non-ablative dual-wavelength treatment when it launched over a decade ago.

It remains a trusted, widely recognised platform in clinics around the world.

But the device landscape has changed. Clinic economics are tighter, and patient expectations are higher. A growing number of practitioners require a resurfacing solution that aligns with modern workflows without the overhead of a legacy console system. That is the gap MultiFrax was built to fill.

This article presents a straightforward comparison of MultiFrax and Fraxel Dual across the key areas that matter most to clinic owners and practitioners: wavelength capability, portability, cost of ownership, clinical flexibility, and day-to-day usability.

The Shared Foundation: 1550nm and 1927nm

Both devices are built around the same dual-wavelength principle that has become the gold standard in non-ablative fractional resurfacing.

The 1550nm erbium fibre wavelength penetrates deeper into the dermis, addressing textural issues such as acne scars, fine lines, wrinkles, stretch marks, and overall skin laxity. The 1927nm thulium wavelength works more superficially, targeting pigmentation, sun damage, dyschromia, and early melasma.

Published clinical evidence supports the use of both wavelengths in combination for more complete results than either wavelength alone. A multi-centre study published in the Journal of Drugs in Dermatology demonstrated moderate improvement in photodamage severity with combined 1550/1927nm treatment, alongside excellent tolerability and no major adverse events.

In this respect, MultiFrax and the Fraxel Dual operate on the same proven clinical foundation. The differences lie in how each platform delivers those wavelengths, and what that means for your clinic.

Where MultiFrax Differs from the Fraxel Dual

Simultaneous Dual-Wavelength Delivery

The Fraxel Dual allows practitioners to choose either the 1550nm or 1927nm wavelength per pass, switching between them during a session. MultiFrax takes this a step further with its patented SimulScan technology, which fires both wavelengths simultaneously in a single pass. This allows practitioners to address both deep textural issues and surface pigmentation at the same time. This eliminates the need for repeated sequential passes over the treatment area.

The clinical advantage is efficiency: fewer passes, shorter treatment times, and a lower cumulative thermal load on surrounding tissue. For patients, this can lead to improved comfort and a streamlined session. For clinics, this means the ability to treat more patients each day.

True Portability

The Fraxel Dual is a console-based system. It requires a dedicated room, a power outlet, and a fibre-optic cable connecting the base unit to the handpiece. This is the standard form factor for most fractional lasers on the market.

MultiFrax reimagines this completely. The laser source sits inside a lightweight handpiece powered by a rechargeable lithium battery that provides over four hours of continuous use.

There is no console, no wall cable, and no fibre-optic delivery system. Practitioners clip in the battery, attach the handpiece, and are treatment-ready in seconds in any room, at any location.

This portability also provides a technical benefit. Because the laser source is placed within millimetres of the skin rather than metres away via a fibre-optic connection, the beam arrives with less dispersion. The result is a finer, more precise 150μm micro-column, which can contribute to improved comfort during treatment and more controlled thermal zones.

Cost of Ownership and Per-Treatment Economics

This is where the comparison becomes particularly compelling for clinic owners. Traditional console-based fractional lasers, such as the Fraxel Dual, have considerable costs. These can include expensive initial purchase or lease prices, continuous service contracts, consumable tips, and the overhead involved with dedicating a room to a large device.

MultiFrax offers up to 90% lower cost per use than competing platforms. Each multi-treatment tip delivers approximately two million shots, which is enough for seven full-face treatments, five décolletage sessions, and ten hand treatments.

The device requires no external cooling system, no fibre-optic replacements, and no annual calibration. For clinics wanting to offer fractional resurfacing without the financial burden of a traditional system, the economics are significantly more favourable.

Precision and Operator Guidance

The Fraxel Dual uses an intelligent optical tracking system that adjusts pulse delivery to hand speed, distributing treatment zones evenly across the skin. It is a successful approach that has helped standardise treatment quality for years.

MultiFrax offers a comparable level of treatment control through its SmartSense™ real-time feedback system, which visually signals the operator when handpiece speed and contact quality are optimal. The device also provides adjustable scan widths (2-14mm) and flexible micro-column spacing (0.5-2mm), allowing practitioners to tailor treatment density precisely to each patient’s phototype and clinical indication.

What About the Fraxel FTX?

In April 2025, Bausch Health launched the Fraxel FTX, the next-generation successor to the Fraxel Dual. It provides genuine improvements to the Fraxel Dual:

• A handpiece with a 20% reduction in weight and size, and integrated cooling.
• An updated AccuTRAC tracking system.
• A modernised console interface.

The FTX remains a console-based system that requires a dedicated room, fibre-optic delivery, and the associated infrastructure. There is no indication that FTX has implemented simultaneous dual-wavelength firing.

This is the main distinction. The FTX is a refinement of the existing Fraxel model. Where the FTX has made the console experience better, MultiFrax has removed the console entirely.

The Fraxel FTX is a strong device from a reputable brand. But for practitioners whose priorities centre on portability, treatment efficiency, and reduced operating costs, MultiFrax offers a unique set of advantages that the FTX update does not address.

Who Should Consider MultiFrax?

MultiFrax is designed for practitioners and clinic owners who want the clinical capability of a premium fractional resurfacing system without the traditional barriers to entry.

It is particularly ideal for:

• Clinics that want to add fractional laser resurfacing to their menu without the need for a large console and dedicated room.
• Practitioners who want to treat across multiple locations and need a system that travels with them.
• Established laser clinics seeking to lower their cost per treatment while maintaining or improving clinical results.
• Clinics seeking a long-term investment in a growing device category.

It is not a matter of whether the Fraxel Dual is a good device. It is.

It has an excellent clinical track record and strong brand recognition with patients.

The question is whether, in 2026, the traditional console model remains the best option for your specific clinic environment, patient base, and growth plans.

The Bottom Line

The Fraxel Dual has established a reputation as a category-defining device. It introduced millions of patients and practitioners to the benefits of dual-wavelength non-ablative resurfacing, and it remains a respected name in the field.

MultiFrax is built on the same proven wavelength foundation, but delivers it in a fundamentally different way. It is portable, fires both wavelengths simultaneously, costs significantly less to run, and is designed for the way modern clinics actually work.

It offers the clinical depth of a full-sized system with the flexibility, accessibility, and economics that today’s practitioners increasingly demand.

For UK clinics considering fractional resurfacing, whether for the first time or as a replacement for an existing platform, MultiFrax represents a compelling alternative worth serious consideration.

Ready to See MultiFrax in Action?

Book a hands-on demonstration with the AMP team. Fill out a contact form or call 01727 482 432 to arrange your demo.

The post MultiFrax vs Fraxel Dual: How Do The Lasers Compare? appeared first on Aesthetic Medical Partnership.

Moving beyond surface-level trends, the session focuses on the biological foundations that underpin treatment outcomes in both hair and skin restoration. Dr Rob explains how matrix conditioning directly impacts cell communication, tissue response and ultimately the consistency of clinical results.

Drawing on current science and real-world clinical experience, the webinar introduces the concept of structured regenerative protocols designed to support signalling pathways, optimise recovery and improve treatment predictability.

The discussion also examines the role of plant-derived exosome technologies, including EXO|E Skin Revitalising Complex and DE|RIVE Hair Wellness System, and how these can be integrated into everyday practice to support matrix health and enhance regenerative performance.

A valuable session for practitioners looking to deepen their understanding of regenerative medicine and apply it more effectively within clinical practice.

…………………………..

Dr Rob King is Vice President of Sales at Aesthetic Management Partners and a medically trained physician with over a decade of experience in aesthetic and regenerative medicine. He holds a Doctor of Medicine from the University of Illinois, completed training in General Surgery, and earned a degree in Molecular Physiology with a minor in Biochemistry. His background in cellular science and clinical medicine underpins his evidence-led approach to regenerative protocols. Dr King also serves in the Army National Guard with over 20 years of distinguished service.

The post Why the Matrix Matters: Understanding Secretome Signalling in Hair and Skin Restoration with EXO|E and DE|RIVE appeared first on Aesthetic Medical Partnership.